Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $200 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Olivia Brayer has reiterated a Neutral rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a $200 price target.
July 12, 2023 | 1:22 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cantor Fitzgerald has reiterated a Neutral rating on Alnylam Pharmaceuticals and maintained a $200 price target.
The reiteration of a Neutral rating by Cantor Fitzgerald indicates that the analyst believes the stock is fairly valued at its current price. The maintenance of the $200 price target suggests that the analyst does not foresee significant price movement in the near term. This could lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100